



BLUE STAR

Consumer Durables

07 August 2024

# Strong quarter; outlook bright

- Topline jumps 28.7% in Q1, with gross margin rising 140bps and EBITDA margin 180bps
- UCP segment surges 44.3% in Q1; market share steady at 13.75%; management reaffirms 25%-30% revenue growth in FY25
- We raise FY25E/FY26E EPS by 2%/4%, introduce FY27 estimates, and value the stock at 44x P/E. We set a new TP of Rs 1,870. Maintain BUY

**Robust quarter:** BLSTR's Q1FY25 revenue increased 29% YoY to Rs 28.6bn, in line with our estimates. EBITDA jumped 64% YoY to Rs 2.3bn, surpassing our estimates due to robust performances across all verticals. The unitary cooling product (UCP) and electromechanical project (EMP) segments continued to thrive, fuelling management's optimism for FY25 growth. EBITDA margin expanded by 180bps YoY and 100bps QoQ to 8.3%. APAT surged to Rs 1.68bn, a strong 102% YoY increase. The company's carry-forward order book as of Jun'24 grew ~14%, setting a record at Rs 60.8bn.

**UCP segment shines:** The UCP division grew a robust 44.3% YoY, driven by a severe nationwide heatwave, achieving a strong EBIT margin of 9.1%. This performance surpassed Lloyd's EBIT margin of 3.3%. BLSTR is rapidly gaining market share and now commands 13.75% of the market, near its FY25 target of 15%. Management is optimistic about reaching this goal by FY25, bolstered by strategic brand building, a broader product portfolio, and enhanced distribution efforts.

**EMP business hits new heights:** The EMP division delivered a striking topline of Rs 10.3bn with an EBIT margin of 9.9% in Q1, showcasing notable gains sequentially and YoY. This robust margin, up 240bps QoQ and 290bps YoY, marks a new high for the segment. The order book jumped 13% YoY to Rs 45bn, fuelled by a surge in commercial air conditioning systems, underscoring the division's dynamic performance and growth trajectory.

**Maintain BUY, raise TP to Rs 1,870:** BLSTR's UCP business was robust in Q1 and its EMP business has a robust order backlog along with the benefit of strong industry tailwinds. We raise our FY25/FY26 EPS estimates by 2%/4% on the back of the strong quarterly performance and buoyant outlook for FY25. Also, we introduce our FY27 estimates. Upon rolling forward valuations to Jun'26E, our TP increases to Rs 1,870 (from Rs 1,670), based on an unchanged target P/E of 44x. Our target multiple is at ~20% premium to the stock's five-year average. Maintain BUY.

Arshia Khosla research@bobcaps.in

#### Key changes

	Target	Rating	
Ticker/Pr	ice	BLSTR IN/Rs 1,622	
Market c	ар	US\$ 3.7bn	
Free floa	t	61%	
3M ADV		US\$ 9.0mn	
52wk hig	h/low	Rs 1,898/Rs 702	
Promote	r/FPI/DII	39%/11%/25%	

Source: NSE | Price as of 7 Aug 2024

#### Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	96,854	117,577	138,311
EBITDA (Rs mn)	6,649	9,242	11,345
Adj. net profit (Rs mn)	4,150	6,006	7,548
Adj. EPS (Rs)	21.5	31.2	39.2
Consensus EPS (Rs)	21.5	30.0	37.0
Adj. ROAE (%)	21.1	21.1	22.3
Adj. P/E (x)	75.3	52.0	41.4
EV/EBITDA (x)	47.0	33.8	27.5
Adj. EPS growth (%)	59.6	44.7	25.7
Courses Company, Bloomhore, BOD			

Source: Company, Bloomberg, BOBCAPS Research

#### Stock performance



Source: NSE





# Fig 1 – Quarterly performance

Particulars (Rs mn)	Q1FY25	Q1FY24	YoY (%)	Q4FY24	QoQ (%	BOBCAP Est. Q1FY25E	Variance (%)
Revenue	28,654	22,260	28.7	33,278	(13.9)	28,938	(1.0)
EBITDA	2,378	1,450	64.0	2,419	(1.7)	2,003	18.7
EBITDA Margin (%)	8.3	6.5	179bps	7.3	103bps	6.9	140bps
Depreciation	280	228		283			
Interest	76	180		122			
Other Income	238	94		124			
PBT	2,259	1,136	98.9	2,138	5.7		
Tax	573	302		544			
Adjusted PAT	1,687	834	102.3	1,597	5.6	1,271	32.7
Exceptional item							
Reported PAT	1,687	834	102.3	1,597	5.6		
Adj. PAT Margin (%)	5.9	3.7	210bps	4.8	110bps		
EPS (Rs)	8.8	4.3	102.3	8.3	5.9		


Source: Company, BOBCAPS Research

# Fig 2 – Segmental performance

(Rs mn)	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25
Revenues													
Electro- Mechanical Projects And Packaged AC systems	5,052	7,234	8,299	11,399	7,934	9,591	10,030	12,526	9,491	10,772	11,823	15,068	10,390
yoy growth (%)	61.7	33.8	41.7	46.2	57.0	32.6	20.9	9.9	19.6	12.3	17.9	20.3	9.5
Professional Electronics & Industrial Systems	414	616	667	776	527	924	862	1,035	784	837	1,035	1,121	969
yoy growth (%)	7.0	44.5	46.8	55.9	27.2	49.9	29.3	33.4	48.9	(9.4)	20.1	8.3	23.5
Unitary Products	5,054	4,547	6,097	10,367	11,242	5,248	7,050	12,677	11,985	7,295	9,554	17,089	17,295
yoy growth (%)	83.9	42.7	23.7	32.6	122.5	15.4	15.6	22.3	6.6	39.0	35.5	34.8	44.3
EBIT													
Electro- Mechanical Projects And Packaged AC systems	200	465	524	758	452	607	717	992	666	653	967	1,125	1,030
Margin (%)	4.0	6.4	6.3	6.7	5.7	6.3	7.1	7.9	7.0	6.1	8.2	7.5	9.9
Professional Electronics & Industrial Systems	56	98	128	143	59	138	110	198	105	122	152	136	96
Margin (%)	13.4	16.0	19.1	18.5	11.2	14.9	12.7	19.2	13.4	14.6	14.7	12.1	9.9
Unitary Products	218	233	388	721	911	324	518	1,070	893	616	679	1,414	1,580
Margin (%)	4.3	5.1	6.4	7.0	8.1	6.2	7.4	8.4	7.5	8.4	7.1	8.3	9.1

Source: Company, BOBCAPS Research







#### Fig 3 – Revenue growth trend

Source: Company, BOBCAPS Research

### Fig 5 – Net profit trend




Source: Company, BOBCAPS Research




### Fig 7 – PEIS vertical's growth trend

Source: Company, BOBCAPS Research | PEIS: Professional. Electronics and Industrial Systems

## Fig 4 – EBITDA growth trend




### Fig 6 – EMP vertical's growth trend



Source: Company, BOBCAPS Research

### Fig 8 – UCP vertical's growth trend



Source: Company, BOBCAPS Research



# Earnings call highlights

### **Electro-Mechanical Products**

- Segment performance: In the EMP business, the company reported topline of Rs 10.3bn for Q1, ~10% growth YoY. EBIT margin for Q1 stood at 9.9%. Margin here is expected to hover at 7.5-8% and management believes that 20-35% revenue growth is possible here.
- Order book: The company ended the year with a Rs 45bn order book, growth of 12.9% over Q1FY24, due to growth coming in from commercial air conditioner systems.
- Electromechanical projects and market dynamics: Despite limited traction in the commercial building sector, the electromechanical projects business experienced robust bookings from the factories and data center sectors. This growth was largely driven by ongoing government efforts to encourage manufacturing investments through Production-Linked Incentive (PLI) initiatives. Also, there was a noticeable increase in inquiries from the healthcare and retail sectors. The railway electrification sector saw a consistent inflow of inquiries and tenders, although there was a slowdown in order finalisations in the power and metro railway sectors.
- Commercial Air Conditioning Systems: The demand for commercial air conditioning systems in the government sector remained subdued. However, increased demand from the education, manufacturing, and retail sectors more than compensated by driving revenue growth during the quarter. Price revisions and prudent cost management contributed to improved margins. Strong demand continued in tier-3 and -4 cities, with significant orders primarily driven by ducted systems and VRF (variable refrigerant flow) chillers
- Market position: The company maintained its top position in conventional and inverter ducted air conditioning systems and ranked among the top three players in India in scroll chillers, VRF, and screw chillers. This quarter also saw the expansion of the product range with the commercial launch of state-of-the-art chillers for data centre replication and brine chillers. With these new product lines, the company is confident of penetrating new market segments, especially with high-margin products, leading to a significant improvement in EMP's margin in Q1FY25 compared to Q1FY24.
- International business: Demand in the Middle East and Africa remained subdued during the quarter. Despite this, the company is strategically focusing its international business efforts to address market needs accordingly. Investments in R&D are ongoing to expand the product portfolio and enhance offerings. BLSTR's subsidiaries in the US and Europe are actively engaging with customers, and management expects business activity in these regions to pick up traction soon.

## **Unitary Cooling Products**

 Segment performance: The UCP segment grew 44.3% YoY with topline of Rs 17.2bn during Q1.



- Cooling and Purification Products: The cooling and purification products business experienced exceptionally strong growth this quarter, particularly for room air conditioners (RACs), driven by seasonal demand and unusually high temperatures. The demand exceeded inventory plans, but the company successfully capitalised on this by ramping up production. Despite a 50% increase in production, some market demand in May was unmet. Margins for the quarter improved due to volume growth, which enhanced operating leverage. The performance in Q1FY25 was exceptional, and the company remains optimistic about growth prospects for the entire year.
- RAC market: The RAC market grew 65-75% in Q1FY25, which is expected to be the peak of this summer season. Management expects the RAC industry to grow by 20-25% annually, and expects BLSTR to grow at 25-30%.
- **Market share:** The company estimates its market share to remain at 13.75%, which is flat QoQ.
- Commercial refrigeration business: The commercial refrigeration market, including deep freezers, water coolers, and modular cold rooms, continued to grow at a CAGR of 15%. However, regulatory changes for water coolers announced in the last week of Mar'24 impacted sales in Q1FY25. Although production and sales normalised in Q2FY25, the substantial reduction in water cooler sales resulted in lower-than-expected revenue growth and profitability for Q1FY25. Despite this, the company maintains its leadership in key categories such as deep freezer storage, water coolers, and modular cold rooms.
- Market outlook and growth prospects: The outlook for the commercial refrigeration market remains strong, and the company expects to accelerate its growth in the coming quarters. Continued investments in research and development and strategic focus on meeting market demands are expected to drive sustained growth. The company's leadership in key product categories and ability to adapt to regulatory changes position it well for future expansion and profitability.
- Profitability: EBIT margin for Q1 stood at 9.1% which is 160bps expansion vs Q1FY24.

### **Professional Electronics and Industrial Systems**

- Segment performance: The PEIS business showed healthy performance as well, with revenue growth at ~24% in Q1. Q1FY25 EBIT margin was 350bps lower at 9.9%. While most product categories performed well, supply chain disruptions and cost overruns in the MedTech business impacted segment margins.
- Positive business outlook and robust order books: Despite challenges, the year started on a positive note with robust demand for BLSTR's product portfolio. The outlook for the remainder of the year remains favourable, with expectations of sustained growth driven by ongoing market trends and the launch of new products. The company is pleased to announce that its order books remain robust, reflecting the sustained confidence and trust placed in them by esteemed customers and partners. This strong order book is indicative of continued growth and a positive trajectory for the business.



## Other highlights

- Capex: The company's capex plan for the current year is around Rs 4.5bn. Over the next two to three years, this expenditure could range between Rs 7.5bn and Rs 8bn. This aligns with the previously indicated capex plan, and the company remains committed to it. Any new developments will be assessed as they arise.
- QIP funds utilisation: The funds raised through the Qualified Institutional Placement (QIP) in September last year were allocated for specific purposes, including cab manufacturing, R&D, digitalisation, and growing working capital needs. These funds were utilised as planned, supporting the company's strategic initiatives and operational requirements.
- Liquidity profile: The net cash balance stood at Rs 10bn, compared to net borrowing of Rs 2bn in Q1FY24.
- Profitability: Gross and EBITDA margins expanded during the quarter and the year ended Mar'24, largely due to better raw material pricing. Adjusted PAT grew 2x to Rs 1.5bn in Q1.



# Valuation methodology

BLSTR's UCP business demonstrated exceptional strength in Q1, while its EMP segment benefitted from a robust order backlog and favourable industry tailwinds. In response to this strong quarterly performance and promising outlook for FY25, we have raised our FY25/FY26 EPS estimates by 2% and 4%, respectively. Also, we introduce FY27 estimates. As we roll forward our valuations to Jun'26, our TP rises to Rs 1,870 (from Rs 1,670), maintaining a P/E ratio of 44x. This new TP reflects ~20% premium over the stock's five-year average. We continue to maintain our BUY recommendation.

### Fig 9 – Revised estimates

Deutieulere (De ma)		New			Old			Change (%)	
Particulars (Rs mn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Sales	117,577	138,311	162,501	113,231	127,907	NA	3.8	8.1	NA
EBITDA	9,242	11,345	13,927	9,064	10,895	NA	2.0	4.1	NA
PAT	6,006	7,548	9,407	5,880	7,227	NA	2.1	4.4	NA
EPS (Rs)	31.2	39.2	48.8	30.5	37.5	NA	2.1	4.4	NA
EBITDA Margin (%)	7.9	8.2	8.6	8.0	8.5	NA	(10bps)	(30bps)	NA

Source: Company, BOBCAPS Research

# **Key risks**

Key downside risks to our estimates are:

- inability to expand UCP market share amid rising industry competition, and
- weakness in the EMP order book.

# Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Amber Enterprises	AMBER IN	1.7	4,286	4,200	HOLD
Blue Star	BLSTR IN	3.7	1,622	1,870	BUY
Crompton Greaves	CROMPTON IN	3.3	435	520	BUY
Dixon Technologies	DIXON IN	8.2	11,607	13,800	BUY
Havells India	HAVL IN	13.6	1,824	1,900	HOLD
KEI Industries	KEII IN	4.4	4,137	4,100	HOLD
Orient Electric	ORIENTEL IN	0.7	261	300	HOLD
Polycab India	POLYCAB IN	12.0	6,707	7,100	HOLD
Syrma SGS	SYRMA IN	0.9	416	450	HOLD
V-Guard Industries	VGRD IN	2.4	473	440	HOLD
Voltas	VOLT IN	5.8	1,470	1,410	HOLD

Source: BOBCAPS Research, NSE | Price as of 7 Aug 2024



# Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	79,773	96,854	117,577	138,311	162,501
EBITDA	4,928	6,649	9,242	11,345	13,927
Depreciation	848	976	1,176	1,335	1,475
EBIT	4,080	5,673	8,066	10,010	12,452
Net interest inc./(exp.)	(547)	(581)	(527)	(519)	(566)
Other inc./(exp.)	309	474	522	600	690
Exceptional items	0	0	0	0	0
EBT	3,842	5,567	8,061	10,091	12,576
Income taxes	1,243	1,429	2,056	2,543	3,169
Extraordinary items	(1,400)	0	0	0	0
Min. int./Inc. from assoc.	4	5	0	0	0
Reported net profit	4,001	4,150	6,006	7,548	9,407
Adjustments	(1,400)	0	0	0	0
Adjusted net profit	2,601	4,150	6,006	7,548	9,407

Balance Sheet
---------------

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Accounts payables	25,112	26,166	37,045	43,577	51,199
Other current liabilities	8,358	10,746	13,045	15,346	18,030
Provisions	0	0	0	0	0
Debt funds	6,620	2,429	4,787	5,190	5,661
Other liabilities	595	740	893	1,046	1,225
Equity capital	193	411	411	411	411
Reserves & surplus	13,114	25,690	30,347	36,547	44,605
Shareholders' fund	13,307	26,101	30,758	36,958	45,016
Total liab. and equities	53,991	66,183	86,529	102,118	121,131
Cash and cash eq.	2,473	3,774	9,955	13,770	17,907
Accounts receivables	15,488	19,526	23,266	27,626	32,306
Inventories	14,334	14,072	19,105	21,284	25,706
Other current assets	10,211	13,029	15,817	18,606	21,860
Investments	0	0	0	0	0
Net fixed assets	8,813	9,800	11,124	12,289	13,314
CWIP	609	1,081	1,312	1,543	1,813
Intangible assets	0	0	0	0	0
Deferred tax assets, net	0	0	0	0	0
Other assets	2,062	4,902	5,950	7,000	8,224
Total assets	53,991	66,183	86,529	102,118	121,131

#### Cash Flows

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	2,474	2,892	8,799	8,387	8,831
Capital expenditures	(1,821)	(4,333)	(2,500)	(2,500)	(2,500)
Change in investments	342	(1,012)	0	0	0
Other investing cash flows	(337)	98	(1,127)	(1,128)	(1,316)
Cash flow from investing	(1,817)	(5,246)	(3,627)	(3,628)	(3,816)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	717	(4,392)	2,358	403	471
Interest expenses	0	0	0	0	0
Dividends paid	(1,627)	8,040	(1,348)	(1,348)	(1,348)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(911)	3,648	1,009	(945)	(878)
Chg in cash & cash eq.	(254)	1,294	6,182	3,814	4,138
Closing cash & cash eq.	2,473	3,774	9,955	13,770	17,907

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27E
Reported EPS	20.8	21.5	31.2	39.2	48.8
Adjusted EPS	13.5	21.5	31.2	39.2	48.8
Dividend per share	6.0	7.0	7.0	7.0	7.0
Book value per share	69.1	135.5	159.7	191.9	233.
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27E
EV/Sales	3.9	3.2	2.7	2.3	1.9
EV/EBITDA	63.4	47.0	33.8	27.5	22.4
Adjusted P/E	120.2	75.3	52.0	41.4	33.
P/BV	23.5	12.0	10.2	8.5	6.9
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27
Tax burden (Net profit/PBT)	67.7	74.5	74.5	74.8	74.
Interest burden (PBT/EBIT)	94.2	98.1	99.9	100.8	101.
EBIT margin (EBIT/Revenue)	5.1	5.9	6.9	7.2	7.
Asset turnover (Rev./Avg TA)	9.1	9.9	10.6	11.3	12.
Leverage (Avg TA/Avg Equity)	0.8	0.5	0.4	0.4	0.
Adjusted ROAE	22.1	21.1	21.1	22.3	23.
Ratio Analysis					
Ratio Analysis Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27
Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27
•	<b>FY23A</b> 32.0	<b>FY24A</b> 21.4	<b>FY25E</b> 21.4	<b>FY26E</b> 17.6	
Y/E 31 Mar YoY growth (%)			-		17.
Y/E 31 Mar YoY growth (%) Revenue	32.0	21.4	21.4	17.6	17. 22.
Y/E 31 Mar YoY growth (%) Revenue EBITDA	32.0 42.2	21.4 34.9	21.4 39.0	17.6 22.8	17. 22.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS	32.0 42.2	21.4 34.9	21.4 39.0	17.6 22.8	17. 22. 24.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%)	32.0 42.2 55.1	21.4 34.9 59.6	21.4 39.0 44.7	17.6 22.8 25.7	17. 22. 24. 8.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin	32.0 42.2 55.1 6.2	21.4 34.9 59.6 6.9	21.4 39.0 44.7 7.9	17.6 22.8 25.7 8.2	17. 22. 24. 8. 7.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	32.0 42.2 55.1 6.2 5.1	21.4 34.9 59.6 6.9 5.9	21.4 39.0 44.7 7.9 6.9	17.6 22.8 25.7 8.2 7.2	FY271 17. 22. 24. 8. 7. 5. 23.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin	32.0 42.2 55.1 6.2 5.1 3.3	21.4 34.9 59.6 6.9 5.9 4.3	21.4 39.0 44.7 7.9 6.9 5.1	17.6 22.8 25.7 8.2 7.2 5.5	17. 22. 24. 8. 7. 5.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE	32.0 42.2 55.1 6.2 5.1 3.3 22.1	21.4 34.9 59.6 6.9 5.9 4.3 21.1	21.4 39.0 44.7 7.9 6.9 5.1 21.1	17.6 22.8 25.7 8.2 7.2 5.5 22.3	17. 22. 24. 8. 7. 5. 23.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	32.0 42.2 55.1 6.2 5.1 3.3 22.1	21.4 34.9 59.6 6.9 5.9 4.3 21.1	21.4 39.0 44.7 7.9 6.9 5.1 21.1	17.6 22.8 25.7 8.2 7.2 5.5 22.3	17. 22. 24. 8. 7. 5. 23.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days)	32.0 42.2 55.1 6.2 5.1 3.3 22.1 17.9	21.4 34.9 59.6 6.9 5.9 4.3 21.1 18.9	21.4 39.0 44.7 7.9 6.9 5.1 21.1 20.0	17.6 22.8 25.7 8.2 7.2 5.5 22.3 20.4	17. 22. 24. 8. 7. 5. 23. 21.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables	32.0 42.2 55.1 6.2 5.1 3.3 22.1 17.9 71	21.4 34.9 59.6 6.9 4.3 21.1 18.9 74	21.4 39.0 44.7 7.9 6.9 5.1 21.1 20.0 72	17.6 22.8 25.7 8.2 7.2 5.5 22.3 20.4 73	17. 22. 24. 8. 7. 5. 23. 21.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory	32.0 42.2 55.1 6.2 5.1 3.3 22.1 17.9 71 66	21.4 34.9 59.6 6.9 4.3 21.1 18.9 74 53	21.4 39.0 44.7 7.9 6.9 5.1 21.1 20.0 72 59	17.6 22.8 25.7 8.2 7.2 5.5 22.3 20.4 73 56	17. 22. 24. 8. 7. 5. 23. 21. 7 5. 5.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables	32.0 42.2 55.1 6.2 5.1 3.3 22.1 17.9 71 66	21.4 34.9 59.6 6.9 4.3 21.1 18.9 74 53	21.4 39.0 44.7 7.9 6.9 5.1 21.1 20.0 72 59	17.6 22.8 25.7 8.2 7.2 5.5 22.3 20.4 73 56	17. 22. 24. 8. 7. 5. 23. 21. 7 5.
Y/E 31 Mar YoY growth (%) Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables Ratios (x)	32.0 42.2 55.1 6.2 5.1 3.3 22.1 17.9 71 66 115	21.4 34.9 59.6 6.9 4.3 21.1 18.9 74 53 99	21.4 39.0 44.7 7.9 6.9 5.1 21.1 20.0 72 59 115	17.6 22.8 25.7 8.2 7.2 5.5 22.3 20.4 73 56 115	17. 22. 24. 8. 7. 5. 23. 21. 7 5. 11

Adjusted debt/equity Source: Company, BOBCAPS Research | Note: TA = Total Assets

Net interest coverage ratio

7.5

0.5

9.8

0.1

15.3

0.2

19.3

0.1

22.0

0.1



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

# Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

 $BUY-\mbox{Expected return}>+15\%$ 


HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Ratings and Target Price (3-year history): BLUE STAR (BLSTR IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### **General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.